Proteomics of Severe Traumatic Brain Injury: A Feasibility Study

February 20, 2009 updated by: University of Calgary

The purpose of this study is to:

  1. Determine the temporal course of matrix metalloproteinase (MMP) expression in patients wiht severe traumatic brain injury
  2. Determine the temporal course of the expression of MMP-related inflammatory mediators of secondary injury in patients with severe traumatic brain injury
  3. Describe the association of physiological changes and standard microdialysis analyte measures (lactate, pyruvate, lactate/pyruvate ratio, and glucose) to MMP and neuroinflammatory marker concentrations.

Study Overview

Status

Unknown

Conditions

Study Type

Observational

Enrollment (Anticipated)

8

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Canada
    • Alberta
      • Calgary, Alberta, Canada, T2N 2T9
        • Recruiting
        • Foothills Medical Centre
        • Contact:
        • Principal Investigator:
          • David A Zygun, MD
        • Sub-Investigator:
          • John Hurlbert, MD
        • Sub-Investigator:
          • Ian Parney, MD
        • Sub-Investigator:
          • Walter Hader, MD
        • Sub-Investigator:
          • Clare Gallagher, MD
        • Sub-Investigator:
          • Wee Yong, P.hD
        • Sub-Investigator:
          • Christopher Doig, MD
        • Sub-Investigator:
          • Paul Kubes, MD
        • Sub-Investigator:
          • Andreas Kramer, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

All patients referred to Foothills Medical Centre, the regional trauma centre for Southern Alberta

Description

Inclusion Criteria:

  • Patient is 18 years of age or older
  • Patient has GCS less than 9
  • Patient requires intracranial pressure monitoring
  • Patient life expectancy greater than 72 hours

Exclusion Criteria:

  • Patient's TBI is greater than 24 hours old
  • Patient is less than 18 years of age
  • Patient does not require intracranial pressure monitoring
  • Patient has life expectancy less than 72 hours
  • Patient has GCS greater or equal to 9
  • Patient is currently enrolled in another study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Calgary

Collaborators

Canadian Intensive Care Foundation

Investigators

  • Principal Investigator: Zygun A David, MD, University of Calgary

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2007

Study Completion (Anticipated)

August 1, 2009

Study Registration Dates

First Submitted

August 27, 2007

First Submitted That Met QC Criteria

August 27, 2007

First Posted (Estimate)

August 29, 2007

Study Record Updates

Last Update Posted (Estimate)

February 24, 2009

Last Update Submitted That Met QC Criteria

February 20, 2009

Last Verified

February 1, 2009

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 20216 (University of Kansas)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe